KRAS and cancer: Like the cancer-associated mutations, NS-associated mutations result in accumulation of GTP-bound KRAS through enhanced nucleotide exchange or impaired GTP hydrolysis, albeit to a lesser extent than the cancer-associated variants (Gremer et al., 2011; Schubbert et al., 2007).